Patent SG-11201810631S-A (SG)
Title: Compositions and methods for tumor vaccination using prostate cancer-associated antigens
Inventor: JONES FRANK
IPC: C12N15/86
Filed: 2017-06-02
Abstract: TripleGene Insert for Prostate Cancer Vaccine Prostate Stern Cell Antigen (PSCA) PA PSA T2A Prostate Specific Membrane Antigen (PSMA) 2A sequence with Gly-Ser-Gly linker from Porcine teschovirus-1 2A sequence with Gly-Ser-Gly linker from Thosea asigna virus (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) WIP0 I PCT IiiimmoimiolollmolommioloiollmoiliniovoimIE (10) International Publication Number WO 2017/210562 Al (51) International Patent Classification: A61K 39/39 (2006.01) A61N 5/10 (2006.01) A61K 39/395 (2006.01) Cl 2N 15/86 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/US2017/035694 (22) International Filing Date: 02 June 2017 (02.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/345,582 03 June 2016 (03.06.2016) US (71) Applicant: ETUBICS CORPORATION [US/US]; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). (72) Inventors: JONES, Frank, R.; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). BALINT, Joseph; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). LATCHMAN, Yvette; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). RICE, Adrian; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). GABITZSCH, Elizabeth; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). (74) Agent: RAMANATHAN, Renuka et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: COMPOSITIONS AND METHODS FOR TUMOR VACCINATION USING PROSTATE CANCER-ASSOCIATED AN- TIGENS Possible Prostate Cancer Multi-Antigen Gene Construct for Insertion into Ad5 LE1-, E2b-] FIG. 10A (57) : Methods and compositions for constructing and producing recombinant adenovirus- based vector vaccines are provid- ed. In particular aspects, there are be provided compositions and methods involving adenovirus vectors comprising genes for target antigens, such as pro state-specific antigen (PSA), pro state- specific membrane antigen (PSMA), MUC1, CEA, and/or Brachyury, and costimulatory molecules for use in treatment methods that generate highly reactive anti-tumor immune responses and that allows for multiple vaccinations in individuals with preexisting immunity to adenovirus. [Continued on next page] WO 2017/210562 Al MIDEDIMOM010101110101110010i0101REIEDIDIIMOVOIS Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))